Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

clofarabine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor

Related drugs:

‹

captisol-enabled melphalan (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

carmustine (14)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine-releasing intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

›

No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	clofarabine Sensitive: A2 - Guideline clofarabine Sensitive : A2	clofarabine Sensitive: A2 - Guideline clofarabine Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	clofarabine Sensitive: A2 - Guideline clofarabine Sensitive : A2	clofarabine Sensitive: A2 - Guideline clofarabine Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	clofarabine + idarubicin hydrochloride Sensitive: A2 - Guideline clofarabine + idarubicin hydrochloride Sensitive : A2	clofarabine + idarubicin hydrochloride Sensitive: A2 - Guideline clofarabine + idarubicin hydrochloride Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: A2 - Guideline cytarabine + clofarabine Sensitive : A2	cytarabine + clofarabine Sensitive: A2 - Guideline cytarabine + clofarabine Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	clofarabine Sensitive: A2 - Guideline clofarabine Sensitive : A2	clofarabine Sensitive: A2 - Guideline clofarabine Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3